Table 1.

Summary of findings from genetically engineered mice indicating antihypertrophic action of natriuretic peptide/GC signal pathway

Model	Cardiac phenotypes
ANP KO (Wang et al., 2003)	Hypertrophy at baseline and exacerbated hypertrophy and fibrosis under pressure-overload
Corin KO (Chan et al., 2005)	Hypertension and cardiac hypertrophy
NPR-A KO (Oliver et al., 1997; Knowles et al., 2001; Franco et al., 2004; Tokudome et al., 2005)	Cardiac hypertrophy and sudden death at baseline; exacerbated hypertrophy by calcineurin activation or by pressure-overload
Cardiac NPR-A KO (Holtwick et al., 2003)	Mild hypertrophy, hypotension at baseline; exaggerated pressure-overload hypertrophy
TG-DN-NPR-A (Patel et al., 2005)	Increased severity of pressure-overload hypertrophy and fibrosis
NPR-A TG (Kishimoto et al., 2001)	Reduced heart size
TG-CA-GC (Zahabi et al., 2003)	Inhibited hypertrophy by isoproterenol or pressure-overload

Abbreviations: ANP, atrial natriuretic peptide; CA, constitutively active; DN, dominant negative; KO, knockout; NPR-A, natriuretic peptide receptor-A; TG, transgenic.